Direxion mRNA ETF
MSGR
MSGR was delisted on the 21st of April, 2023.
4 hedge funds and large institutions have $1.94M invested in Direxion mRNA ETF in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$601K |
| 2 |
Citigroup
New York
|
+$601K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$601K |
| 4 |
JP Morgan Chase
New York
|
+$162K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of America
Charlotte,
North Carolina
| $594K | +$601K | +25,000 | New |
|
|
2
Citigroup
New York
| $594K | +$601K | +25,000 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $594K | +$601K | +25,000 | New |
|
|
4
JP Morgan Chase
New York
| $160K | +$162K | +6,729 | New |
|
MSGR Hedge Fund Activity: Q4 2021 in Review
4 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Direxion mRNA ETF (MSGR) for Q4 2021, worth a combined $1.94M.
Buyers outnumbered sellers: 4 funds opened new MSGR positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $601K.
- 4 institutional investors held Direxion mRNA ETF (MSGR) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $1.94M of Direxion mRNA ETF stock for Q4 2021.
- 4 funds opened new Direxion mRNA ETF positions in Q4 2021 and 0 closed out, a net change of +4 holders.
- The largest Direxion mRNA ETF buyer in Q4 2021 was Bank of America, an estimated $601K added.
Based on aggregated 13F filings for Q4 2021.